Published Online
on November 21, 2002

A more recent version of this article appeared on December 1, 2002

This Article Full Text (PDF) All Versions of this Article: 33/12/2794    most recent 01.STR.0000043674.99741.9Bv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by ApSimon, H. T. Articles by Popovic, E. A. Search for Related Content PubMed PubMed Citation Articles by ApSimon, H. T. Articles by Popovic, E. A. Related Collections Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage Aneurysm, AVM, hematoma

Submitted on July 9, 2002
Accepted on July 25, 2002

A Population-Based Study of Brain Arteriovenous Malformation. Long-Term Treatment Outcomes

H. T. ApSimon FRACR^*; H. Reef FRCP; R. V. Phadke MD; and E. A. Popovic FRACS

From the Interventional Neuroradiology Unit (H.T.A.) and Departments of Neurology Department (H.R.), Neurosurgery (E.A.P.), and Neuroradiology (R.V.P.), Royal Perth Hospital, Perth, Western Australia.

^* To whom correspondence should be addressed. E-mail: lisa.kelly{at}health.wa.gov.au.

Background and Purpose—By undertaking long-term follow-up of a functionally isolated population study group, we sought to achieve a true picture of intrinsic brain arteriovenous malformation (BAVM). We sought to assess the validity of earlier population-based series and to determine the effects of newer treatment methods on the overall morbidity and mortality of BAVM.

Methods—We excluded other intracranial vascular pathologies by defining criteria. By retrospective and prospective study, 240 patients with BAVM were followed for a mean of 10.11 years from first diagnosis.

Results—Death rates were as follows: all causes, 12.9%; all BAVM related, 8.75%; BAVM related during conservative management, 24.6%; and BAVM related during active management, 3.9% (P=0.031). Mean diagnosis-to-death interval was 10.6 years. Oxford neurological disability scale grades of 209 survivors (July 2001) were as follows: grades 0 to 2, 74.1%; grade 3, 17.2%; and grades 4 to 5, 9.5%. Death rates were higher for patients who had bled or suffered nonhemorrhagic neurological deficit at original presentation. Incidence of first-ever hemorrhage in untreated patients was as follows: 0 to 9 years, 4.6% (P=0.0035); 30 to 39 years, 21% (P=0.02); and 60 to 69 years, 40.0% (P=0.045). The first bleed was fatal in 4.6%.

Conclusions—We find no evidence of a substantial undiagnosed reservoir of nonsymptomatic BAVM. All BAVM are potentially hazardous. The great majority of BAVM patients become symptomatic during the patient's lifetime, and the majority will bleed. The risk of first hemorrhage is lifelong and rises with age. Compared with earlier population-based series, our low overall patient mortality is predominantly due to higher proportions of active treatment in the 1980s and 1990s.

Key words: cerebral arteriovenous malformations • epidemiology • hemorrhage • mortality • treatment outcome

This article has been cited by other articles:

				J. van Beijnum, J. J. Bhattacharya, C. E. Counsell, V. Papanastassiou, V. Ritchie, R. C. Roberts, R. J. Sellar, C. Warlow, R. A.-S. Salman, and on behalf of the SIVMS Collaborators Patterns of Brain Arteriovenous Malformation Treatment: Prospective, Population-Based Study Stroke, December 1, 2008; 39(12): 3216 - 3221. [Abstract] [Full Text] [PDF]

				E. S. Roach, M. R. Golomb, R. Adams, J. Biller, S. Daniels, G. deVeber, D. Ferriero, B. V. Jones, F. J. Kirkham, R. M. Scott, et al. Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young Stroke, September 1, 2008; 39(9): 2644 - 2691. [Abstract] [Full Text] [PDF]

				R. M. Friedlander Arteriovenous Malformations of the Brain N. Engl. J. Med., June 28, 2007; 356(26): 2704 - 2712. [Full Text] [PDF]

				J. H. Choi, H. Mast, R. R. Sciacca, A. Hartmann, A. V. Khaw, J. P. Mohr, R. L. Sacco, and C. Stapf Clinical Outcome After First and Recurrent Hemorrhage in Patients With Untreated Brain Arteriovenous Malformation Stroke, May 1, 2006; 37(5): 1243 - 1247. [Abstract] [Full Text] [PDF]

				C. Stapf, A.V. Khaw, R.R. Sciacca, C. Hofmeister, H.C. Schumacher, J. Pile-Spellman, H. Mast, J.P. Mohr, and A. Hartmann Effect of Age on Clinical and Morphological Characteristics in Patients With Brain Arteriovenous Malformation Stroke, November 1, 2003; 34(11): 2664 - 2669. [Abstract] [Full Text] [PDF]